Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists.
about
When is hub gene selection better than standard meta-analysis?Potential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate CancerExpression of cell cycle-regulated genes and prostate cancer prognosis in a population-based cohortPhysioSpace: relating gene expression experiments from heterogeneous sources using shared physiological processesGenome-wide signatures of transcription factor activity: connecting transcription factors, disease, and small moleculesIdentification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data.Intrinsic bias in breast cancer gene expression data sets.A semi-parametric Bayesian model for unsupervised differential co-expression analysisPrediction of breast cancer prognosis using gene set statistics provides signature stability and biological context.Meta-analysis of gene expression microarrays with missing replicates.An integrated genomic approach identifies persistent tumor suppressive effects of transforming growth factor-β in human breast cancerThe co-factor of LIM domains (CLIM/LDB/NLI) maintains basal mammary epithelial stem cells and promotes breast tumorigenesis.Most random gene expression signatures are significantly associated with breast cancer outcome.A target based approach identifies genomic predictors of breast cancer patient response to chemotherapy.Functional analysis of prognostic gene expression network genes in metastatic breast cancer models.A Novel Subset of Human Tumors That Simultaneously Overexpress Multiple E2F-responsive Genes Found in Breast, Ovarian, and Prostate CancersChallenges in Biomarker Discovery: Combining Expert Insights with Statistical Analysis of Complex Omics Data.Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.Gene expression profiling in human lung development: an abundant resource for lung adenocarcinoma prognosis.Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.Identifying gnostic predictors of the vaccine response.Prognostic signatures in breast cancer: correlation does not imply causation.Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung CancerThe origins of breast cancer prognostic gene expression profilesClinically available RNA profiling tests of prostate tumors: utility and comparisonValidation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinomaA transcriptional and metabolic signature of primary aneuploidy is present in chromosomally unstable cancer cells and informs clinical prognosisCharacteristics and Validation Techniques for PCA-Based Gene-Expression Signatures.Using molecular markers to help predict who will fail after radical prostatectomy.Prognostic determinants in prostate cancer.Commercially available prognostic molecular models in early-stage lung cancer: a review of the Pervenio Lung RS and Myriad myPlan Lung Cancer tests.Maspin influences response to doxorubicin by changing the tumor microenvironment organization.Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence.Single nucleotide polymorphisms in the 20q13 amplicon genes in relation to breast cancer risk and clinical outcome.LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression.Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer.Robust prognostic gene expression signatures in bladder cancer and lung adenocarcinoma depend on cell cycle related genes.Prognostic and predictive biomarkers post curative intent therapy.Proliferation genes in lung development associated with the prognosis of lung adenocarcinoma but not squamous cell carcinoma.Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node-negative breast cancer patients.
P2860
Q21133557-AF15B6F7-EF52-4A1E-87D4-88A149FDCFD0Q26784517-887CBE68-2A50-4A0C-A04D-F709458990DEQ27331050-0016FC3D-967C-43AC-96B6-FCCD885AB3F2Q28534493-52DD4268-A7E8-46CC-A072-3CCB1213C2A5Q28536750-BA49DAEA-2956-4D5D-BBF1-77640ED7C206Q33368855-58AF0B9C-AD81-451D-A47B-19ABAE9DCCC8Q33475987-6D8DF90C-C0FC-45BA-9C2E-A0498A5A8E29Q33575180-E6445B26-2241-4B1C-A59F-B0CE3D5EC699Q33586739-1CB6C9EF-DD48-4DD3-918F-9A6236B8A25AQ33854993-618E2025-9DDC-45A5-B522-9AEB95CF030DQ33892460-12DAF6AE-545B-4F9F-A377-E0333BB587D3Q33981658-784F88AF-9875-4ED9-8107-245BEFA0B016Q34058091-F809BD9E-719C-41D7-9F09-DF7A040CA4CBQ34266467-D6A56306-F95D-4548-AE55-00DD88994AD4Q34450632-29B0A004-44FC-49A4-8E5A-701A801A2608Q34456552-4DFB5EB2-27BC-4BF3-9CAE-CA9B9AB56E94Q34555631-AA254B6F-E2B0-4A6E-A91D-47D16B92825EQ34962331-AC1F9680-E41E-43A7-AF40-16BD49E63E96Q35228753-66FA80F6-4A97-4CF2-B5F8-1201176620B6Q35709269-C4207445-E844-4DF7-ACD4-13B9A442552FQ36059000-E20C1123-E7E1-4FF3-B517-9E70522ABCFEQ36245333-42FCF5FE-F3BA-47D1-8942-321338F3DA5BQ36558386-AD558119-E3C9-49CD-B581-BE2C62D74D43Q37036319-8C30BA37-AF96-4AEA-88B0-6986FD8BF89AQ37113181-B1B902EE-8007-4161-A0F4-78FFAF4B8A4EQ37325311-531A8F82-ABD2-4B4D-B0E6-01FC0A50620FQ37513855-8FF24864-C89A-46B8-9722-44C237187BE4Q37652541-86995E15-28C7-4A77-98A9-07AC49B991A1Q37957896-3D005743-E1E4-42D3-885E-F53FB2404735Q37966912-F8D36529-AE31-4752-9B78-1E2E56298F98Q38432142-2C3BD84D-7AF2-462A-801A-90FC746B2EF1Q39062271-AD7C2237-0410-41A2-A5D6-DF009041F833Q39675735-39A5134C-0B31-4C67-A295-71865790AC45Q39743981-9DA411D1-45D0-49C3-8FD2-34A8FD7DD8F6Q39817827-D6D9ED0B-A86B-42DC-A517-C84EAD89D92AQ40356316-9C290A9A-1854-4419-8C1F-3F67F6011CA2Q41885616-C36895DC-ED70-40BE-B0EA-BD8261C09A34Q43026297-B54E03EF-5AAE-48BD-8C2A-C7CAF013800BQ47371241-9ED2D3FD-A7A6-4A6E-A9D6-5AA60ABC9258Q52935837-9EE413D8-E28A-43A1-BC03-B1A8AF244C39
P2860
Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists.
@ast
Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists.
@en
Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists.
@nl
type
label
Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists.
@ast
Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists.
@en
Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists.
@nl
prefLabel
Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists.
@ast
Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists.
@en
Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists.
@nl
P2860
P356
P1433
P1476
Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists.
@en
P2093
Jonathan D Mosley
Ruth A Keri
P2860
P2888
P356
10.1186/1755-8794-1-11
P577
2008-04-25T00:00:00Z
P5875
P6179
1049889684